Article(id=1322180298201223476, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1322180288214577608, articleNumber=null, orderNo=null, doi=null, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=null, receivedDateStr=null, revisedDate=null, revisedDateStr=null, acceptedDate=1621785600000, acceptedDateStr=2021-05-24, onlineDate=1793161948013, onlineDateStr=2026-10-28, pubDate=1630252800000, pubDateStr=2021-08-30, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1793161948013, onlineIssueDateStr=2026-10-28, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1793161948013, creator=13701087609, updateTime=1793161948013, updator=13701087609, issue=Issue{id=1322180288214577608, tenantId=1146029695717560320, journalId=1235980733773295621, year='2021', volume='30', issue='16', pageStart='1441', pageEnd='1536', issueExtLink='null', onlineDate='null', pubDate='1630252800000', pubDateStr='2021-08-30', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=0, createTime=1793161945632, creator='13701087609', updateTime=1793162101003, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1322180940143644721, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1322180288214577608, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1322180940147839026, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1322180288214577608, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=1483, endPage=1488, ext={EN=ArticleExt(id=1322180298385772853, articleId=1322180298201223476, tenantId=1146029695717560320, journalId=1235980733773295621, language=EN, title=Progress in clinical research on immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma, columnId=null, journalTitle=Chinese Journal of New Drugs, columnName=null, runingTitle=null, highlight=null, articleAbstract=

Hepatocellular carcinoma (HCC) is the main pathological type of primary liver cancer, accounting for 75%~85%, and most of the patients are diagnosed late with poor prognosis. The treatment choices of advanced HCC are limited, sorafenib and other targeted drugs can only prolong the overall survival of patients to about one year, which is difficult to meet the clinical needs, so it is urgent to develop new treatment methods. Nivolumab further prolongs the overall survival of patients, and it was the first immune checkpoint inhibitor (ICI) approved for the treatment of advanced HCC, which also opened the prelude of immunotherapy for advanced HCC. Subsequent clinical studies indicated that immune checkpoint inhibitors (ICIs) combined with other therapies such as targeted therapy, local treatment, systemic chemotherapy could not only enhance the efficacy, but also had no significant increase in adverse reactions. In conclusion, ICIs have broad application prospects in the treatment of advanced HCC, and combination therapy will be the main treatment for advanced HCC.

, authors=Tao LIU, Ding YU, An-qi YANG, Xun-qiang WANG, authorsList=Tao LIU, Ding YU, An-qi YANG, Xun-qiang WANG, authorCompany=null, correspAuthors=Xun-qiang WANG, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1322180298721317174, articleId=1322180298201223476, tenantId=1146029695717560320, journalId=1235980733773295621, language=CN, title=免疫检查点抑制剂在晚期肝细胞癌治疗中的临床研究进展, columnId=1236330553964810454, journalTitle=中国新药杂志, columnName=综述, runingTitle=null, highlight=null, articleAbstract=

原发性肝癌的主要病理类型是肝细胞癌（hepatocellular carcinoma，HCC），占75%~85%，多数患者就诊时病情较晚，预后差。晚期HCC的治疗方式有限，索拉非尼等靶向药物仅能将患者的总生存期延长至1年左右，难以满足临床需要，亟需开发新的治疗方式。纳武利尤单抗进一步延长了患者的总生存期，成为首个获批用于治疗晚期HCC的免疫检查点抑制剂（immune checkpoint inhibitors，ICIs），也拉开了晚期HCC免疫治疗的序幕。随后的临床研究显示ICIs联合其他疗法如靶向治疗、局部治疗、全身化疗等不仅可增强疗效，且不良反应没有明显增加。总之，ICIs在晚期HCC治疗上有广阔的应用前景，联合治疗将是晚期HCC治疗的主要方式。

, authors=刘涛, 于鼎, 杨安琪, 王训强, authorsList=刘涛, 于鼎, 杨安琪, 王训强, authorCompany=null, correspAuthors=王训强, authorNote=, correspAuthorsNote=, copyrightStatement=null, copyrightOwner=《中国新药杂志》有限公司, extLink=null, articleAbsUrl=null, sourceXml=itkXD6NB5Ol5h3HCAvroIA==, magXml=hIKurODxyO9z5W3jNvfdcw==, pdfUrl=null, pdf=u6RuIYQTaVSu/6ocNXFlJw==, pdfFileSize=1347084, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=DJdZj0QeVQ1I+kWZ8g6qUg==, mapNumber=null, fund=null)}, authors=[Author(id=1322180299023307067, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=lt9821@163.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322180299140747581, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, authorId=1322180299023307067, language=EN, stringName=Tao LIU, firstName=Tao, middleName=null, lastName=LIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Clinical Medicine, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing 211100, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322180299203662142, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, authorId=1322180299023307067, language=CN, stringName=刘涛, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=正大天晴药业集团股份有限公司临床医学部，南京　211100, bio={"content":"

刘涛，男，硕士研究生，临床医学经理，主要从事创新药肝胆系统恶性肿瘤临床试验工作。E-mail：lt9821@163.com。

"}, bioImg=null, bioContent=

刘涛，男，硕士研究生，临床医学经理，主要从事创新药肝胆系统恶性肿瘤临床试验工作。E-mail：lt9821@163.com。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322180298901672247, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, xref=null, ext=[AuthorCompanyExt(id=1322180298914255160, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, companyId=1322180298901672247, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Clinical Medicine, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing 211100, China), AuthorCompanyExt(id=1322180298939420985, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, companyId=1322180298901672247, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=正大天晴药业集团股份有限公司临床医学部，南京　211100)])]), Author(id=1322180299274965312, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322180299388211522, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, authorId=1322180299274965312, language=EN, stringName=Ding YU, firstName=Ding, middleName=null, lastName=YU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Clinical Medicine, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing 211100, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322180299467903299, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, authorId=1322180299274965312, language=CN, stringName=于鼎, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=正大天晴药业集团股份有限公司临床医学部，南京　211100, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322180298901672247, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, xref=null, ext=[AuthorCompanyExt(id=1322180298914255160, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, companyId=1322180298901672247, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Clinical Medicine, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing 211100, China), AuthorCompanyExt(id=1322180298939420985, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, companyId=1322180298901672247, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=正大天晴药业集团股份有限公司临床医学部，南京　211100)])]), Author(id=1322180299606315333, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322180299690201415, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, authorId=1322180299606315333, language=EN, stringName=An-qi YANG, firstName=An-qi, middleName=null, lastName=YANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Clinical Medicine, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing 211100, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322180299803447624, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, authorId=1322180299606315333, language=CN, stringName=杨安琪, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=正大天晴药业集团股份有限公司临床医学部，南京　211100, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322180298901672247, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, xref=null, ext=[AuthorCompanyExt(id=1322180298914255160, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, companyId=1322180298901672247, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Clinical Medicine, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing 211100, China), AuthorCompanyExt(id=1322180298939420985, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, companyId=1322180298901672247, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=正大天晴药业集团股份有限公司临床医学部，南京　211100)])]), Author(id=1322180299878945098, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=wxq01@126.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1322180301581832524, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, authorId=1322180299878945098, language=EN, stringName=Xun-qiang WANG, firstName=Xun-qiang, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Clinical Medicine, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing 211100, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322180301678301517, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, authorId=1322180299878945098, language=CN, stringName=王训强, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=正大天晴药业集团股份有限公司临床医学部，南京　211100, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322180298901672247, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, xref=null, ext=[AuthorCompanyExt(id=1322180298914255160, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, companyId=1322180298901672247, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Clinical Medicine, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing 211100, China), AuthorCompanyExt(id=1322180298939420985, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, companyId=1322180298901672247, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=正大天晴药业集团股份有限公司临床医学部，南京　211100)])])], keywords=[Keyword(id=1322180301829296462, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, language=EN, orderNo=1, keyword=advanced hepatocellular carcinoma), Keyword(id=1322180301921571151, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, language=EN, orderNo=2, keyword=immune checkpoint inhibitors), Keyword(id=1322180302018040144, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, language=EN, orderNo=3, keyword=progression of disease), Keyword(id=1322180302143869265, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, language=CN, orderNo=1, keyword=晚期肝细胞癌), Keyword(id=1322180302215172434, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, language=CN, orderNo=2, keyword=免疫检查点抑制剂), Keyword(id=1322180302307447123, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, language=CN, orderNo=3, keyword=疾病进展)], refs=[Reference(id=1322180302424887636, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer J Clin, 2018, 68(6): 394-424., articleTitle=null, refAbstract=null), Reference(id=1322180302491996501, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=OIKONOMOPOULOS G, ARAVIND P, SARKER D. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?[J]. Future Oncol, 2016, 12(4): 465-476., articleTitle=null, refAbstract=null), Reference(id=1322180302575882582, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=LLOVET JM, RICCI S, MAZZAFERRO V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390., articleTitle=null, refAbstract=null), Reference(id=1322180302651380055, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=KUDO M, FINN RS, QIN S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173., articleTitle=null, refAbstract=null), Reference(id=1322180302718488920, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=QIN S, BAI Y, LIM HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013, 31(28): 3501-3508., articleTitle=null, refAbstract=null), Reference(id=1322180302814957913, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502., articleTitle=null, refAbstract=null), Reference(id=1322180302894649690, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=FU J, XU D, LIU Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients[J]. Gastroenterology, 2007, 132(7): 2328-2339., articleTitle=null, refAbstract=null), Reference(id=1322180302970147163, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=LI H, LI CW, LI X, et al. MET inhibitors promote liver tumor evasion of the immune response by stabilizing PDL1[J]. Gastroenterology, 2019, 156(6): 1849-1861., articleTitle=null, refAbstract=null), Reference(id=1322180303024673116, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=LI Z, LI B, DAN P, et al. Expression and clinical significance of PD1 in hepatocellular carcinoma tissues detected by a novel mouse anti-human PD1 monoclonal antibody[J]. Int J Oncol, 2018, 52(6): 2079-2092., articleTitle=null, refAbstract=null), Reference(id=1322180303095976285, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=MAKAROVA-RUSHER OV, MEDINA-ECHEVERZ J, DUFFY AG, et al. The Yin and Yang of evasion and immune activation in HCC[J]. J Hepatol, 2015, 62(6): 1420-1429., articleTitle=null, refAbstract=null), Reference(id=1322180303163085150, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=KAMIMURA H, YAMAGIWA S, TSUCHIYA A, et al. Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence[J]. J Hepatol, 2012, 56(2): 381-388., articleTitle=null, refAbstract=null), Reference(id=1322180303238582623, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=WHERRY EJ, KURACHI M. Molecular and cellular insights into T cell exhaustion[J]. Nat Rev Immunol, 2015, 15(8): 486-499., articleTitle=null, refAbstract=null), Reference(id=1322180303301497184, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=BUONAGURO L, MAURIELLO A, CAVALLUZZO B, et al. Immunotherapy in hepatocellular carcinoma[J]. Ann Hepatol, 2019, 18(2): 291-297., articleTitle=null, refAbstract=null), Reference(id=1322180303360217441, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=YEN CJ, MARKMAN B, CHAO Y, et al. Preliminary results of a phase IA/IB study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb), in patients with advanced hepatocellular carcinoma[J]. Ann Oncol, 2017, 28(Suppl 3): S54., articleTitle=null, refAbstract=null), Reference(id=1322180303439909218, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHU AX, FINN RS, EDELINE J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7): 940-952., articleTitle=null, refAbstract=null), Reference(id=1322180303515406691, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=FINN RS, RYOO BY, MERLE P, et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC)[J]. J Clin Oncol, 2019, 37(Suppl 15): S4004., articleTitle=null, refAbstract=null), Reference(id=1322180303603487076, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=YAU T, PARK JW, FINN RS, et al. CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)[J]. Ann Oncol, 2019, 30(Suppl 5): S874-S875., articleTitle=null, refAbstract=null), Reference(id=1322180303674790245, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=QIN S, REN Z, MENG Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial[J]. Lancet Oncol, 2020, 21(4): 571-580., articleTitle=null, refAbstract=null), Reference(id=1322180303746093414, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=SEGAL NH, HAMID O, HWU W, et al. 1058PD-A phase I multi-arm dose-expansion study of the anti-programmed cell death-ligand-1 (PD-L1) antibody MEDI4736: preliminary data[J]. Ann Oncol, 2014, 25(Suppl 4): S365., articleTitle=null, refAbstract=null), Reference(id=1322180303825785191, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=SANGRO B, GOMEZ-MARTIN C, DE LA MATA M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C[J]. J Hepatol, 2013, 59(1): 81-88., articleTitle=null, refAbstract=null), Reference(id=1322180303892894056, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=XU J, ZHANG Y, JIA R, et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study[J]. Clin Cancer Res, 2019, 25(2): 515-523., articleTitle=null, refAbstract=null), Reference(id=1322180304010334569, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=YUNG-JUE B, TALIA G, LAETITIA D, et al. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)[J]. Eur J Cancer, 2020, 137(2020): 272-284., articleTitle=null, refAbstract=null), Reference(id=1322180304098414954, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=KUDO M, MOTOMURA K, WADA Y, et al. First-line avelumab+axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100)[J]. J Clin Oncol, 2019, 37(Suppl 15): S4072., articleTitle=null, refAbstract=null), Reference(id=1322180304173912427, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=LLOVET J, SHEPARD KV, FINN RS, et al. 747P-A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results[J]. Ann Oncol, 2019, 30(Suppl 5): S286-S287., articleTitle=null, refAbstract=null), Reference(id=1322180304249409900, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=FINN RS, QIN S, IKEDA M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905., articleTitle=null, refAbstract=null), Reference(id=1322180304320713069, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=KUDO M, IKEDA M, MOTOMURA K, et al. A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117[J]. J Clin Oncol, 2020, 38(Suppl 4): S513., articleTitle=null, refAbstract=null), Reference(id=1322180305973268846, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=KELLEY RK, ABOU-ALFA GK, BENDELL JC, et al. Phase Ⅰ/Ⅱ study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase Ⅰ safety and efficacy analyses[J]. J Clin Oncol, 2017, 35(Suppl 15): S4073., articleTitle=null, refAbstract=null), Reference(id=1322180306052960623, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=HE AR, YAU T, HSU C, et al. Nivolumab (NIVO)+ ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040[J]. J Clin Oncol, 2020, 38(Suppl 4): S512., articleTitle=null, refAbstract=null), Reference(id=1322180306124263792, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=QIN S, CHEN Z, LIU Y, et al. A phase II study of anti-PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer[J]. J Clin Oncol, 2019, 37(Suppl 15): S4074., articleTitle=null, refAbstract=null), Reference(id=1322180306212344177, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=VIVEIROS P, RIAZ A, LEWANDOWSKI RJ, et al. Current state of liver-directed therapies and combinatory approaches with systemic therapy in hepatocellular carcinoma (HCC)[J]. Cancers, 2019, 11(8): 1085., articleTitle=null, refAbstract=null), Reference(id=1322180306292035954, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=DUFFY AG, ULAHANNAN SV, MAKOROVA-RUSHER O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2017, 66(3): 545-551., articleTitle=null, refAbstract=null), Reference(id=1322180306367533427, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=AGDASHIAN D, ELGINDI M, XIE CQ, et al. The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma[J]. Cancer Immunol Immun, 2019, 68(4): 599-608., articleTitle=null, refAbstract=null), Reference(id=1322180306434642292, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=夏琳, 宋媛媛, 郝瑞敏, 等. 我国晚期肾细胞癌临床试验关注要点的考虑[J]. 中国新药杂志, 2021, 30(10): 871-875., articleTitle=null, refAbstract=null), Reference(id=1322180306510139765, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=汪龙, 金荣, 韩一萱, 等. 免疫检查点抑制剂致急性肾损伤的研究进展[J]. 中国新药杂志, 2021, 30(1): 38-42., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1322180298901672247, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, xref=null, ext=[AuthorCompanyExt(id=1322180298914255160, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, companyId=1322180298901672247, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Clinical Medicine, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing 211100, China), AuthorCompanyExt(id=1322180298939420985, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322180298201223476, companyId=1322180298901672247, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=正大天晴药业集团股份有限公司临床医学部，南京　211100)])], figs=null, attaches=null, journal=Journal(id=1235980159023624194, delFlag=0, nameCn=中国新药杂志, nameEn=Chinese Journal of New Drugs, nameHistory1=null, nameHistory2=null, issn=1003-3734, eissn=null, cn=11-2850/R, coden=ZXZHA6, periodic=3, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=ohPEEN//Vz1tDT3ZBNTp4Q==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of New Drugs, journalRemark=null, publicationField=null, createdTime=1772610233314, updatedTime=1788948968376, createdBy=18614031015, updatedBy=13041195026, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=ohPEEN//Vz1tDT3ZBNTp4Q==, picEn=f9WK9bvTM4guTmS/iGhOMg==, jcr=null, cjcr=null, exts=[JournalExt(id=1304509780974924039, language=CN, name=中国新药杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1788948968404, updatedTime=1788948968404, createdBy=13041195026, updatedBy=13041195026, submissionGuidelinesUrl=, submissionAuthorUrl=http://draft.newdrug.cn/journalx_zgxy/authorLogOn.action, submissionEditorUrl=http://draft.newdrug.cn/journalx_zgxy/editorLogOn.action, submissionReviewUrl=http://draft.newdrug.cn/journalx_zgxy/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1304509781025255688, language=EN, name=Chinese Journal of New Drugs, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1788948968416, updatedTime=1788948968416, createdBy=13041195026, updatedBy=13041195026, submissionGuidelinesUrl=, submissionAuthorUrl=http://draft.newdrug.cn/journalx_zgxy/authorLogOn.action, submissionEditorUrl=http://draft.newdrug.cn/journalx_zgxy/editorLogOn.action, submissionReviewUrl=http://draft.newdrug.cn/journalx_zgxy/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1235980733773295621, websiteList=[Website(id=1235982099191222761, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1235980733773295621, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgxyzz/CN, language=CN, createTime=1772610695884, createBy=18614031015, updateTime=1772610860397, updateBy=18614031015, name=中国新药杂志-中文, tplId=1146099689490845704, title=中国新药杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1235983918629966444, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=articleTextType, value=kx, createTime=1772611129672, updateTime=1772611129672, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918604800617, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=banner, value=null, createTime=1772611129666, updateTime=1772611129666, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918655132271, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=grayFlag, value=0, createTime=1772611129678, updateTime=1772611129678, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918596412008, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=logo, value=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/file/pic?fileId=W567vm71kFC7UhK9TSU6xw==, createTime=1772611129664, updateTime=1772611129664, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918667715185, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=minRunFlag, value=0, createTime=1772611129681, updateTime=1772611129681, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918617383531, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/file/pic, createTime=1772611129669, updateTime=1772611129669, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918659326576, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=silenceFlag, value=0, createTime=1772611129679, updateTime=1772611129679, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918613189226, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1772611129668, updateTime=1772611129668, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918634160749, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=themeColor, value=null, createTime=1772611129673, updateTime=1772611129673, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918646743662, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=themeStyle, value=null, createTime=1772611129676, updateTime=1772611129676, creator=18614031015, updator=18614031015)]), Website(id=1235982099270914542, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1235980733773295621, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgxyzz/EN, language=EN, createTime=1772610695903, createBy=18614031015, updateTime=1772610875891, updateBy=18614031015, name=中国新药杂志-英文, tplId=1146101810881728533, title=Chinese Journal of New Drugs, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1235983955829248630, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=articleTextType, value=kx, createTime=1772611138541, updateTime=1772611138541, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955804082803, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=banner, value=null, createTime=1772611138535, updateTime=1772611138535, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955854414457, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=grayFlag, value=0, createTime=1772611138547, updateTime=1772611138547, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955795694194, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=logo, value=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/file/pic?fileId=W567vm71kFC7UhK9TSU6xw==, createTime=1772611138533, updateTime=1772611138533, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955866997371, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=minRunFlag, value=0, createTime=1772611138550, updateTime=1772611138550, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955820860021, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/file/pic, createTime=1772611138539, updateTime=1772611138539, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955862803066, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=silenceFlag, value=0, createTime=1772611138549, updateTime=1772611138549, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955812471412, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1772611138537, updateTime=1772611138537, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955837637239, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=themeColor, value=null, createTime=1772611138543, updateTime=1772611138543, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955846025848, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=themeStyle, value=null, createTime=1772611138545, updateTime=1772611138545, creator=18614031015, updator=18614031015)])], journalTitle=中国新药杂志, weixinUrl=null, journalUrl=http://www.newdrug.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of New Drugs, journalPhotoCn=ohPEEN//Vz1tDT3ZBNTp4Q==, journalPhotoEn=f9WK9bvTM4guTmS/iGhOMg==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/Y2021/V30/I16/1483, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/Y2021/V30/I16/1483, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/PDF/Y2021/V30/I16/1483, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/PDF/Y2021/V30/I16/1483, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1630252800000, fullTextJson=null, articleText=null, reference=null)